Literature DB >> 25853270

[Angiogenin, bFGF and VEGF: angiogenic markers in breath condensate of patients with pulmonary hypertension].

H-J Seyfarth1, U Sack2, C Gessner1, H Wirtz1.   

Abstract

Pulmonary arterial hypertension (PAH) is associated with a change in vascular architecture. A characteristic histological feature is the plexiform lesion. Similar alterations are observed in the pulmonary vascular bed of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Cytokines involved in angiogenesis were found in both serum and lung tissue of patients with PAH and CTEPH, although their role in the formation of plexiform lesions remains unclear. The examination of breath condensate is a noninvasive technique to analyse proteins possibly associated with the pathogenesis of various lung diseases.Breath condensate of 22 patients with pulmonary hypertension (PAH: n = 12; CTEPH: n = 10) and 7 healthy volunteers was examined using a multiplex fluorescent bead immunoassay to determine the concentrations of the biomarkers angiogenin, bFGF, VEGF, IL-8, and TNF-α. Significantly higher levels of angiogenin, bFGF and TNF-α were observed in breath condensate of patients with pulmonary hypertension in comparison to healthy controls. Similarly, breath condensate levels of VEGF were elevated in patients with PAH as against healthy volunteers. However, IL-8 levels in breath condensate did not differ between the two groups. The data suggest that breath condensate of patients with pulmonary hypertension is characterized by increased levels of the angiogenic factors angiogenin, VEGF and bFGF as well as TNF-α, but not IL-8. A larger study is needed to confirm these results and to determine the prognostic and therapeutic implications of these findings. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25853270     DOI: 10.1055/s-0034-1391775

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  5 in total

Review 1.  Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.

Authors:  Vanessa Rameh; Antoine Kossaify
Journal:  Biomark Insights       Date:  2016-06-23

2.  VEGF Promoter Polymorphism Confers an Increased Risk of Pulmonary Arterial Hypertension in a Chinese Population.

Authors:  Yufeng Zhuo; Qingchun Zeng; Peng Zhang; Guoyang Li; Qiang Xie; Ying Cheng
Journal:  Yonsei Med J       Date:  2017-03       Impact factor: 2.759

3.  Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Authors:  Christopher J Rhodes; Pavandeep Ghataorhe; John Wharton; Kevin C Rue-Albrecht; Charaka Hadinnapola; Geoffrey Watson; Marta Bleda; Matthias Haimel; Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Andrew J Peacock; Joanna Pepke-Zaba; Mark R Toshner; S John Wort; J Simon R Gibbs; Allan Lawrie; Stefan Gräf; Nicholas W Morrell; Martin R Wilkins
Journal:  Circulation       Date:  2016-11-21       Impact factor: 29.690

4.  Circular RNA-HIPK3 regulates human pulmonary artery endothelial cells function and vessel growth by regulating microRNA-328-3p/STAT3 axis.

Authors:  Liuqing Hong; Xiaoying Ma; Jiyuan Liu; Yinzhu Luo; Jincai Lin; Ying Shen; Liyan Zhang
Journal:  Pulm Circ       Date:  2021-03-29       Impact factor: 3.017

5.  Hypoxia in utero increases the risk of pulmonary hypertension in rat offspring and is associated with vasopressin type‑2 receptor upregulation.

Authors:  Hao Ding; Yuchuan Luo; Ke Hu; Huaying Huang; Pei Liu; Mengqing Xiong; Li Zhu; Jing Yi; Ying Xu
Journal:  Mol Med Rep       Date:  2020-09-23       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.